Document is current
Any future updates will be listed below
-
Authors
Bauer, Katrin I.
Baker, Dhanwin
Lerner, Raissa
Koeck, Thomas
Buch, Gregor
Fischer, Zlatka
Martens, Robin
Esenkova, Ekaterina E.
Nuber, Maximilian
Andrade-Navarro, Miguel A.
ten Cate, Vincent
Tenzer, Stefan
Wild, Philipp S.
Bindila, Laura
Araldi, Elisa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02932436 at ClinicalTrials.govDocuments that mention this clinical trial
156 Effects of a low-energy meal replacement programme on reverse cardiac remodelling in asymptomatic people with type 2 diabetes: a comparison between south asians and white europeans
https://doi.org/10.1136/heartjnl-2022-bcs.156
Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial
https://doi.org/10.1186/s12933-025-02916-0
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus—results from the randomized, double-blind, placebo-controlled EmDia trial
https://doi.org/10.1007/s00392-023-02164-w
-
Funding
Funding for this research was provided by:
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
- License Information
-
More Information
Article History
Received: 20 November 2024
Accepted: 21 August 2025
First Online: 8 September 2025
Declarations
:
: The local data protection officer and the responsible ethics committee approved the study protocol [ref. no. 2018-13064] prior to study initiation. All study participants provided written informed consent prior to study enrolment. The Declaration of Helsinki [] and the recommendations of good clinical practice and good epidemiological practice were followed in all study procedures.
: Not applicable.
: Philipp S. Wild reports grants from Bayer AG; non-financial grants from Philips Medical Systems; grants and consulting fees from Boehringer Ingelheim, Novartis AG, Sanofi-Aventis GmbH, and Daiichi Sankyo Europe GmbH; grants and consulting and lecturing fees from Bayer Healthcare Pharmaceuticals; lecturing fees from Pfizer Inc. and Bristol Myers Squibb; consulting fees from AstraZeneca plc; consulting fees and non-financial support from DiaSorin; and non-financial support from I.E.M. Gregor Buch was employed solely at the University Medical Center Mainz during the analysis period and is currently employed by Boehringer Ingelheim. This work was not sponsored by Boehringer Ingelheim and the views of the manuscript do not represent the views of Boehringer Ingelheim.
: Open Access, this article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit .
